Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny Inc. has experienced significant growth, as evidenced by a 39% year-over-year increase in egg retrievals and bankings, highlighting the demand for its fertility solutions among women, particularly in the tech sector. The company is poised to capitalize on expanding markets, with potential revenue opportunities stemming from a standard coverage package and the introduction of a fully-insured product offering, especially as more states implement IVF mandates. Furthermore, with near-100% client retention and a growing number of covered lives accessing ancillary services, Progyny appears well-positioned for sustained growth and increased investor confidence moving forward.

Bears say

The financial outlook for Progyny Inc. appears negative due to several fundamental factors, including economic uncertainty and potential unemployment challenges that could discourage individuals from utilizing fertility benefits. Notably, the company has revised its guidance downward, with expected covered lives decreasing from 7.6 million to 7.2 million, contributing to concerns about future revenue growth. Additionally, despite elevated utilization rates, which may have been influenced by large company layoffs, the adjusted EBITDA forecast remains below previous estimates, signaling potential operational weaknesses in a competitive market.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.